HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50
MT NewswiresMay 1 11:05 ET
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating
MT NewswiresApr 29 06:45 ET
Bristol-Myers Squibb Analyst Ratings
BenzingaApr 26 09:31 ET
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating
MT NewswiresApr 26 07:37 ET
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Laboratory (LH) and Bristol-Myers Squibb (BMY)
TipRanksApr 26 05:25 ET
Bristol-Myers Squibb: Hold Rating Amid Mixed Performance and Future Revenue Concerns
TipRanksApr 26 05:19 ET
Barclays Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
TipRanksApr 26 04:47 ET
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating
MT NewswiresApr 25 11:52 ET
Bristol-Myers Squibb: A Hold Rating Amid Mixed Financial Outlook and Upcoming Strategic Updates
TipRanksApr 25 05:35 ET
Bristol-Myers Squibb Analyst Ratings
BenzingaApr 18 11:03 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)
TipRanksApr 18 06:10 ET
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58
MT NewswiresApr 12 07:37 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY) and Roche Holding AG (OtherRHHVF)
TipRanksApr 12 06:00 ET
Bristol-Myers Squibb: A Buy Rating on Undervaluation and Promising Product Portfolio
TipRanksApr 12 05:25 ET
Hold Rating on Bristol-Myers Squibb Amid Promising Yet Incomplete KarXT Schizophrenia Trial Data
TipRanksApr 10 02:18 ET
Bristol-Myers Squibb's Hold Rating: Balancing KarXT's Efficacy and Safety With Financial Uncertainties
TipRanksApr 8 05:47 ET
Wells Fargo Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)
TipRanksApr 3 05:16 ET
BTIG Upgrades Nuvation to Buy, Cites AnHeart Acquisition
Seeking AlphaMar 26 13:37 ET
Hold Rating on Bristol-Myers Squibb Amidst NSCLC Trial Uncertainties and Pending KarXT Results
TipRanksMar 19 01:37 ET
Hold Rating on Bristol-Myers Squibb Amid Mixed Clinical Outcomes and Market Competition
TipRanksMar 18 05:15 ET
No Data
No Data